Daiichi Sankyo, Lilly Drug At Top Of U.S. FDA List For Investigation
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's and U.S. drug maker Eli Lilly's co-developed Effient (prasugrel) blood-thinner leads a U.S. FDA list of drugs on a schedule of planned investigations